Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma

International Journal of Medical Sciences

Volumn 7, Issue 1, 2010, Pages 48-54

  Kuwahara, Akiko ^a   Yamamori, Motohiro ^b   Nishiguchi, Kohshi ^c,d   Okuno, Tatsuya ^c   Chayahara, Naoko ^c   Miki, Ikuya ^c   Tamura, Takao ^c   Kadoyama, Kaori ^b   Inokuma, Tsubasa ^b   Takemoto, Yoshiji ^b   Nakamura, Tsutomu ^c   Kataoka, Kazusaburo ^a   Sakaeda, Toshiyuki ^b,c  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Circadian rhythm; Dose escalation; Esophageal squamous cell carcinoma; Plasma concentration

Indexed keywords

CISPLATIN; FLUOROURACIL;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CHEILITIS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE; LEUKOPENIA; MALE; RADIATION DOSE; STOMATITIS; TREATMENT DURATION;

EID: 76149105836     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.7.48     Document Type: Article

References (26)

1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-7.
2. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Eng J Med 1992; 326: 1593-8.
3. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996; 276: 637-9.
4. Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15: 277-84.
5. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915-21.
6. Kaneko K, Ito H, Konishi K, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 2003; 88: 18-24.
7. Tahara M, Ohtsu A, Hironaka S, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005; 35: 316-23.
8. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003; 21: 2697-702.
9. Kumekawa Y, Kaneko K, Ito H, et al. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 2006; 41: 425-32.
10. Sakaeda T, Yamamori M, Kuwahara A, et al. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev 2009; 61: 388-401.
11. Miki I, Tamura T, Nakamura T, et al. Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther Drug Monit 2005; 27: 369-74.
12. Okuno T, Tamura T, Yamamori M, et al. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for Stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol 2007; 30: 252-7.
13. Sakaeda T, Yamamori M, Kuwahara A, et al. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther Drug Monit 2008; 30: 497-503.
14. Yamashita H, Nakagawa K, Tago M, et al. The experience of concurrent chemoradiation for Japanese patients with superficial esophageal squamous cell carcinoma: a retrospective study. Am J Clin Oncol 2005; 28: 555-9.
15. Yamashita H, Nakagawa K, Yamada K, et al. A single institutional non-randomized retrospective comparison between definitive chemoradiotherapy and radical surgery in 82 Japanese patients with resectable esophageal squamous cell carcinoma. Dis Esophagus 2008; 21: 430-6.
16. Yamashita H, Nakagawa K, Tago M, et al. The intergroup/RTOG 85-01 concurrent chemoradiation regimen for Japanese esophageal cancer. Hepatogastroenterology 2006; 53: 863-8.
17. Yamashita H, Nakagawa K, Tago M, et al. Treatment results of preoperative concurrent chemoradiotherapy followed by surgery for Stage III or IV esophageal squamous cell carcinoma. Radiat Med 2006; 24: 65-71.
18. Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 2004; 34: 615-9.
19. Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001; 31: 419-23.
20. Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003; 57: 425-33.
21. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group (The Clinical Trial Review Committee of the Japan Clinical Oncology Group). Jpn J Clin Oncol 1993; 23: 250-7.
22. Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 2002; 19: 177-89.
23. Lévi F, Focan C, Karaboué A, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 2007; 59: 1015-35.
24. Altinok A, Lévi F, Goldbeter A. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci 2009; 36: 20-38.
25. Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201.
26. Zeng ZL, Sun J, Guo L, et al. Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients. Chronobiol Int 2005; 22: 741-54.